January 31, 2015     Japanese 
	  Network - Home
JCN Newswire
  Home  |  Companies  | Annual Reports  |  CSR  | News Alerts     
News Sectors
Health & Med
IT & Internet
Real Estate
Science & Research
Annual Reports
News Alerts
News Search
Photo Gallery
Client Login
Japan Corporate News Network
About JCN
Privacy Policy
Terms of Use

Eisai Co., Ltd. is a research-based human health care (hhc) company that discovers, develops and markets products throughout the world. Eisai focuses its efforts in three therapeutic areas: integrative neuroscience, including neurology and psychiatric medicines; integrative oncology, which encompasses oncotherapy and supportive-care treatments; and vascular/immunological reaction. Through a global network of research facilities, manufacturing sites and marketing subsidiaries, Eisai actively participates in all aspects of the worldwide healthcare system. 

Company Headquarters 4-6-10 Koishikawa, Bunkyo-ku,Tokyo 112-8088, JAPAN 
Company Telephone +81-3-3817-3724 
Company Stock Code - TSE
 CompanyStock Price - TSE   
Company Stock Code - U.S.
 CompanyStock Price - U.S.
Company CEO Haruo Naito 
Company Sector Alternative Energy 
Company Industries Pharmaceutical
Company Established 1941 
Company Listed 1961 
Company Homepage www.eisai.com
Company Annual Report
Company CSR Report

Headline News for Eisai  

No records were found in the Headlines


Press Releases for Eisai  

Eisai's Phase II Trial of Anticancer Agent Lenvatinib in Renal Cell Carcinoma Meets Primary Endpoint (Jan 30, 2015)

Eisai and Ajinomoto Pharmaceuticals Launch Branched-Chain Amino Acid Formula Livamin Oral Granules in The Philippines (Jan 26, 2015)

Eisai Listed In Global 100 Sustainability Index for Third Consecutive Year (Jan 23, 2015)

Phase III Trial of Antiepileptic Drug Perampanel as Adjunctive Therapy in Patients with Refractory Partial-Onset Seizures Conducted in Asia Including Japan and China Meets Primary Endpoint (Jan 5, 2015)

Eisai Listed for 13th Consecutive Year in FTSE4GOOD Index Series, an Index for Socially Responsible Investment (Dec 17, 2014)

Eisai Demonstrates Efficacy of Investigational Dual Orexin Receptor Antagonist E2006 in Sleep Initiation and Maintenance Data from Phase II Clinical Trial for Insomnia (Dec 10, 2014)

Eisai Presents Results from Phase III Trial of Antiepileptic Drug Fycompa as Adjunctive Therapy for Primary Generalized Tonic-Clonic Seizures (Dec 9, 2014)

Eisai to Present New Research on Halaven (Eribulin) at 37th Annual San Antonio Breast Cancer Symposium (Dec 2, 2014)

Eisai Establishes Holding Company Eisai China Holdings Ltd. in China (Dec 1, 2014)

Eisai Opens New Parenteral Facility in China (Dec 1, 2014)

Eisai Opens New Packaging Facility at Hatfield Production Plant in U.K. (Nov 28, 2014)

Eisai Launches Anticancer Agent Halaven as Company's First Product in Brazil (Nov 26, 2014)

Eisai Launches Antiepileptic Drug Fycompa in Hong Kong (Nov 21, 2014)

Eisai's Ranking Significantly Increases in the Access to Medicine Index 2014 (Nov 17, 2014)

Lorcaserin Meets Primary Endpoint and Confirms Proof-Of-Concept as Potential Aid for Smoking Cessation in Investigational Phase II Clinical Study (Nov 4, 2014)

Eisai Announces Top-Line Results of Investigational Study on Coadministration of Lorcaserin and Phentermine (Oct 29, 2014)

U.S. FDA Accepts sNDA For Antiepileptic Agent Fycompa as Adjunctive Treatment of Primary Generalized Tonic-Clonic Seizures (Oct 21, 2014)

U.S. FDA Grants Priority Review Status to NDA for Anticancer Agent Lenvatinib (Oct 15, 2014)

U.S. FDA Accepts Eisai's sNDA for BANZEL (Rufinamide) as Adjunctive Treatment in Pediatric Patients With Lennox-Gastaut Syndrome (Oct 15, 2014)

U.S. FDA Approves Antiemetic Agent Akynzeo For Prevention Of Chemotherapy-Induced Nausea and Vomiting (CINV) (Oct 14, 2014)

Previous... More...



• Register for News Alerts about Eisai here

• Back to Previous Page

• View more Company Profile Listings

Photo News

Understanding the reinforcing ability of carbon nanotubes
More >> 
Annual Reports

  More >>    
CSR Reports

  More >> 

About JCN | Privacy Policy | Terms of Use | JCN Network (日本語)